New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics WALTHAM, Mass.--(BUSINESS WIRE)-- PerkinElmer, Inc., a ...
No drug developer imagines that every kinase-targeting program can be advanced by any single kinase assay format. Most drug developers recognize that if they are to advance a kinase-targeting program, ...
The emergence of HTS in the early 90s and the quest for better technologies to address the expanding chemical diversity spurred Cisbio, originally a diagnostics company, to diversify and hone its ...
HTRF assays from Cisbio have advanced to cover diverse areas, including G protein-coupled receptors, kinases and cell signaling, epigenetics, and biomarkers. A broad range of toolbox reagents and kits ...
The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer. Kinase drug discovery programs rely on the precise characterization and screening of ...
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced two ready-to-use HTRF® and AlphaLISA® no-wash assay kits designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results